Drug intelligence / Profile preview

olaptesed + bortezomib + dexamethasone

Development stage: Unknown
Lead developer: TME Pharma
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous (olaptesed Pegol, Bortezomib), Oral (dexamethasone)

Overview

This is a combination therapy of three agents: **olaptesed pegol** (a Spiegelmer that binds and inhibits CXCL12/SDF-1), **bortezomib** (a reversible 26S proteasome inhibitor), and **dexamethasone** (a synthetic glucocorticoid corticosteroid). Olaptesed blocks the interaction of CXCL12 with its receptor CXCR4, interfering with the microenvironmental support of malignant plasma cells. Bortezomib induces cancer cell death by inhibiting proteasome-mediated protein degradation, disrupting multiple signaling pathways. Dexamethasone exerts anti-myeloma effects via immunosuppression, apoptosis induction, and anti-inflammatory action. The combination has been evaluated for relapsed/refractory multiple myeloma, showing tolerability and an efficacy profile comparable to other bortezomib-based regimens[1].

Other names: olaptesed pegol + bortezomib + dexamethasone

Targets

PSMB5 (Proteasome subunit beta Type-5)CXCL12 (C-X-C motif chemokine ligand 12)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on olaptesed + bortezomib + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on olaptesed + bortezomib + dexamethasone.

Explore the full profile